VEGF-C promotes the development of lymphatics in bone and bone loss

  1. Devon Hominick
  2. Asitha Silva
  3. Noor Khurana
  4. Ying Liu
  5. Paul C Dechow
  6. Jian Q Feng
  7. Bronislaw Pytowski  Is a corresponding author
  8. Joseph M Rutkowski
  9. Kari Alitalo
  10. Michael T Dellinger  Is a corresponding author
  1. UT Southwestern Medical Center, United States
  2. Texas A&M College of Dentistry, United States
  3. Eli Lilly and Company, United States
  4. Texas A&M College of Medicine, United States
  5. University of Helsinki, Finland

Abstract

Patients with Gorham-Stout disease (GSD) have lymphatic vessels in their bones and their bones gradually disappear. Here we report that mice that overexpress VEGF-C in bone exhibit a phenotype that resembles GSD. To drive VEGF-C expression in bone, we generated Osx-tTA;TetO-Vegfc double-transgenic mice. In contrast to Osx-tTA mice, Osx-tTA;TetO-Vegfc mice developed lymphatics in their bones. We found that inhibition of VEGFR3, but not VEGFR2, prevented the formation of bone lymphatics in Osx-tTA;TetO-Vegfc mice. Radiological and histological analysis revealed that bones from Osx-tTA;TetO-Vegfc mice were more porous and had more osteoclasts than bones from Osx-tTA mice. Importantly, we found that bone loss in Osx-tTA;TetO-Vegfc mice could be attenuated by an osteoclast inhibitor. We also discovered that the mutant phenotype of Osx-tTA;TetO-Vegfc mice could be reversed by inhibiting the expression of VEGF-C. Taken together, our results indicate that expression of VEGF-C in bone is sufficient to induce the pathologic hallmarks of GSD in mice.

Article and author information

Author details

  1. Devon Hominick

    Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center, Dallas, United States
    Competing interests
    No competing interests declared.
  2. Asitha Silva

    Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center, Dallas, United States
    Competing interests
    No competing interests declared.
  3. Noor Khurana

    Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center, Dallas, United States
    Competing interests
    No competing interests declared.
  4. Ying Liu

    Biomedical Sciences, Texas A&M College of Dentistry, Dallas, United States
    Competing interests
    No competing interests declared.
  5. Paul C Dechow

    Biomedical Sciences, Texas A&M College of Dentistry, Dallas, United States
    Competing interests
    No competing interests declared.
  6. Jian Q Feng

    Biomedical Sciences, Texas A&M College of Dentistry, Dallas, United States
    Competing interests
    No competing interests declared.
  7. Bronislaw Pytowski

    Eli Lilly and Company, New York, United States
    For correspondence
    bronek.pytowski@gmail.com
    Competing interests
    Bronislaw Pytowski, During preparation of the manuscript, B. Pytowski was an employee of Eli Lilly and continues to hold stock in the company.
  8. Joseph M Rutkowski

    Department of Medical Physiology, Texas A&M College of Medicine, College Station, United States
    Competing interests
    No competing interests declared.
  9. Kari Alitalo

    Wihuri Research Institute, University of Helsinki, Helsinki, Finland
    Competing interests
    Kari Alitalo, Reviewing editor, eLife.
  10. Michael T Dellinger

    Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center, Dallas, United States
    For correspondence
    michael.dellinger@utsouthwestern.edu
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3315-4239

Funding

The Lymphatic Malformation Institute (Research Grant)

  • Michael T Dellinger

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: The animal experiments described in this manuscript were carried out in accordance with animal protocols (2014-0031 and 2016-101510) approved by the Institutional Animal Care and Use Committee of UT Southwestern Medical Center.

Copyright

© 2018, Hominick et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Devon Hominick
  2. Asitha Silva
  3. Noor Khurana
  4. Ying Liu
  5. Paul C Dechow
  6. Jian Q Feng
  7. Bronislaw Pytowski
  8. Joseph M Rutkowski
  9. Kari Alitalo
  10. Michael T Dellinger
(2018)
VEGF-C promotes the development of lymphatics in bone and bone loss
eLife 7:e34323.
https://doi.org/10.7554/eLife.34323

Share this article

https://doi.org/10.7554/eLife.34323

Further reading

    1. Developmental Biology
    2. Stem Cells and Regenerative Medicine
    Ruben Sebastian-Perez, Shoma Nakagawa ... Maria Pia Cosma
    Research Article

    Chromocenters are established after the 2-cell (2C) stage during mouse embryonic development, but the factors that mediate chromocenter formation remain largely unknown. To identify regulators of 2C heterochromatin establishment in mice, we generated an inducible system to convert embryonic stem cells (ESCs) to 2C-like cells. This conversion is marked by a global reorganization and dispersion of H3K9me3-heterochromatin foci, which are then reversibly formed upon re-entry into pluripotency. By profiling the chromatin-bound proteome (chromatome) through genome capture of ESCs transitioning to 2C-like cells, we uncover chromatin regulators involved in de novo heterochromatin formation. We identified TOPBP1 and investigated its binding partner SMARCAD1. SMARCAD1 and TOPBP1 associate with H3K9me3-heterochromatin in ESCs. Interestingly, the nuclear localization of SMARCAD1 is lost in 2C-like cells. SMARCAD1 or TOPBP1 depletion in mouse embryos leads to developmental arrest, reduction of H3K9me3, and remodeling of heterochromatin foci. Collectively, our findings contribute to comprehending the maintenance of chromocenters during early development.

    1. Developmental Biology
    Yunfei Mu, Shijia Hu ... Hongjun Shi
    Research Article

    Notch signaling has been identified as a key regulatory pathway in patterning the endocardium through activation of endothelial-to-mesenchymal transition (EMT) in the atrioventricular canal (AVC) and proximal outflow tract (OFT) region. However, the precise mechanism underlying Notch activation remains elusive. By transiently blocking the heartbeat of E9.5 mouse embryos, we found that Notch activation in the arterial endothelium was dependent on its ligand Dll4, whereas the reduced expression of Dll4 in the endocardium led to a ligand-depleted field, enabling Notch to be specifically activated in AVC and OFT by regional increased shear stress. The strong shear stress altered the membrane lipid microdomain structure of endocardial cells, which activated mTORC2 and PKC and promoted Notch1 cleavage even in the absence of strong ligand stimulation. These findings highlight the role of mechanical forces as a primary cue for endocardial patterning and provide insights into the mechanisms underlying congenital heart diseases of endocardial origin.